---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000057"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:16:08.304969+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics concludes strategic review, plans $375M capital return

## Summary
- Board unanimously approved $375M excess capital return to stockholders; structure and terms to be announced.
- Strategic review included evaluation of sale, business combination, and continued investment; outreach to third parties and stockholders.
- Company to continue development of lead candidate KER-065 for Duchenne muscular dystrophy.
- 2025 annual meeting results: all three director nominees elected, Deloitte & Touche ratified, executive compensation approved.

## SEC filing metadata
- accession: 0001664710-25-000057
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000057/0001664710-25-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000057/kros-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000057
- JSON: https://secwatch.observer/filing/0001664710-25-000057.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.